{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:40:18Z","timestamp":1793144418066,"version":"4.5.0"},"reference-count":61,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To provide health care providers, patients, and the general public with a responsible assessment of currently available data regarding screening for and management of phenylketonuria (PKU).<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants.<\/jats:title><jats:p>A nonfederal, nonadvocate, 14-member panel representing the fields of pediatrics, genetics, human development, public policy, nursing, and molecular physiology and including patient representatives. In addition, 19 experts in pediatrics, medical genetics, psychology, pediatric neurology, biochemical and molecular genetics, and gene therapy presented data to the panel and to a conference audience of 312.<\/jats:p><\/jats:sec><jats:sec><jats:title>Evidence.<\/jats:title><jats:p>The literature was searched using Medline for January 1980 through July 2000, and an extensive bibliography of 3394 references was provided to the panel. Experts prepared abstracts for their conference presentations with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience.<\/jats:p><\/jats:sec><jats:sec><jats:title>Consensus Process.<\/jats:title><jats:p>The panel, answering predefined questions, developed its conclusions based on the scientific evidence presented in open forum and the scientific literature. The panel composed a draft statement, which was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately after its release at the conference and was updated with the panel's final revisions. The statement is available at http:\/\/consensus.nih.gov.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>Genetic testing for PKU has been in place for almost 40 years and has been very successful in preventing severe mental retardation in thousands of children and adults. Metabolic control is necessary across the lifespan of individuals with PKU. A comprehensive, multidisciplinary, integrated system is needed to delivery of care to individuals with PKU. Greatly needed are consistency and coordination between screening, treatment, data collection, and patient support programs. There should be equal access to culturally sensitive, age-appropriate treatment programs. Ethically sound, specific policies for storage, ownership, and use in future studies of archived samples remaining from PKU testing should be established. Research into the pathophysiology of PKU and relationship to genetic, neural, and behavioral variation is strongly encouraged. Uniform policies must be established to remove financial barriers to the acquisition of medical foods and modified low-protein foods and to provide access to support services needed to maintain metabolic control in individuals with PKU. Research on nondietary alternative treatments for PKU is strongly encouraged. To achieve optimal statistical power and cross-cultural applicability, it will be beneficial to use data acquired via national and international collaboration.phenylketonuria, hyperphenylalanimea, phenylketonuria screening, phenylalanine-restricted diet, maternal phenylketonuria, newborn screening, phenylalanine monitoring, phenylketonuria outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.108.4.972","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"972-982","source":"Crossref","is-referenced-by-count":252,"title":["National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16\u201318, 2000"],"prefix":"10.1542","volume":"108","author":[{"name":"National Institutes of Health Consensus Development Panel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2001,10,1]]},"reference":[{"key":"2021121021534309300_B1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7326\/0003-4819-106-4-531","article-title":"Extracorporeal enzyme reactors for depletion of phenylalanine in phenylketonuria.","volume":"106","author":"Ambrus","year":"1987","journal-title":"Ann Intern Med"},{"key":"2021121021534309300_B2","first-page":"1","article-title":"A report from the Newborn Screening Task Force. Serving the family from birth to the medical home.","volume":"106","author":"American Academy of Pediatrics","year":"2000","journal-title":"Pediatrics"},{"key":"2021121021534309300_B3","first-page":"1499","article-title":"ACMG statement: statement on storage and use of genetic materials.","volume":"57","author":"American College of Medical Genetics Storage of Genetics Materials Committee","year":"1995","journal-title":"Am J Hum Genet"},{"key":"2021121021534309300_B4","first-page":"471","article-title":"ASHG report: statement on informed consent for genetic research.","volume":"59","author":"American Society of Human Genetics","year":"1996","journal-title":"Am J Hum Genet"},{"key":"2021121021534309300_B5","first-page":"35","article-title":"Intellectual development in 12-year-old children treated for phenylketonuria.","volume":"145","author":"Azen","year":"1991","journal-title":"Am J Dis Child"},{"key":"2021121021534309300_B6","first-page":"18","article-title":"Dietary treatment of destructive behavior associated with hyperphenylalaninemia.","volume":"21","author":"Baumeister","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"2021121021534309300_B7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archpedi.1990.02150290033020","article-title":"Valine, isoleucine, and leucin: a new treatment for phenylketonuria.","volume":"336","author":"Berry","year":"1990","journal-title":"Am J Dis Child"},{"key":"2021121021534309300_B8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF01963563","article-title":"Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging.","volume":"150","author":"Bick","year":"1991","journal-title":"Eur J Pediatr"},{"key":"2021121021534309300_B9","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/BF01957228","article-title":"White matter abnormalities in patients with treated hyperphenylalaninemia: magnetic resonance relaxometry and proton spectroscopy findings.","volume":"152","author":"Bick","year":"1993","journal-title":"Eur J Pediatr"},{"key":"2021121021534309300_B10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2788.1999.43120176.x","article-title":"Economic impact of feeding a phenylalanine restricted diet to adults with previously untreated phenylketonuria.","volume":"43","author":"Brown","year":"1999","journal-title":"J Intellect Disabil Res"},{"key":"2021121021534309300_B11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s004310051008","article-title":"Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997.","volume":"158","author":"Burgard","year":"1999","journal-title":"Eur J Pediatr."},{"key":"2021121021534309300_B12","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1203\/00006450-199703000-00011","article-title":"Neuropsychologic functions of early treated patients with phenylketonuria on and off diet: results of a cross-national and cross-sectional study.","volume":"41","author":"Burgard","year":"1997","journal-title":"Pediatr Res"},{"key":"2021121021534309300_B13","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/clinchem\/44.12.2405","article-title":"Use of phenylalanine-to-tyrosine ratio determined by mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours.","volume":"44","author":"Chace","year":"1998","journal-title":"Clin Chem"},{"key":"2021121021534309300_B14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/adc.68.3.426","article-title":"Report of Medical Research Council Working Party on Phenylketonuria. Recommendations on the dietary management of phenylketonuria.","volume":"68","author":"Cockburn","year":"1993","journal-title":"Arch Dis Child"},{"key":"2021121021534309300_B15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1471-0528.1972.tb12903.x","article-title":"Maternal hyperphenylalaninaemia in the normal and phenylketonuric mother and its influence on maternal plasma and fetal fluid amino acid concentrations.","volume":"79","author":"Cockburn","year":"1972","journal-title":"J Obstet Gynaecol Br Comm"},{"key":"2021121021534309300_B16"},{"key":"2021121021534309300_B17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1086\/302938","article-title":"Phenotypes of patients with \u201csimple\u201d Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics.","volume":"66","author":"Dipple","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2021121021534309300_B18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/07315724.1997.10718665","article-title":"Phenylketonuria: current dietary treatment practices in the United States and Canada.","volume":"16","author":"Fisch","year":"1997","journal-title":"J Am Coll Nutr"},{"key":"2021121021534309300_B19","first-page":"3","article-title":"Primary, secondary and meta-analysis of research.","volume":"5","author":"Glass","year":"1976","journal-title":"ER"},{"key":"2021121021534309300_B20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/adc.82.3.216","article-title":"Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia.","volume":"82","author":"Greeves","year":"2000","journal-title":"Arch Dis Child"},{"key":"2021121021534309300_B21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1086\/301920","article-title":"A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype.","volume":"63","author":"Guldberg","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2021121021534309300_B22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1542\/peds.32.3.338","article-title":"A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants.","volume":"32","author":"Guthrie","year":"1963","journal-title":"Pediatrics"},{"key":"2021121021534309300_B23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1542\/peds.104.2.258","article-title":"Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency. Report from the Maternal PKU Collaborative Study.","volume":"104","author":"Gu\u0308ttler","year":"1999","journal-title":"Pediatrics"},{"key":"2021121021534309300_B24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJM198603063141001","article-title":"Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria.","volume":"314","author":"Holtzman","year":"1986","journal-title":"N Engl J Med"},{"key":"2021121021534309300_B25","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/301638","article-title":"Human PAH mutation and hyperphenylalaninemia phenotypes: a meta-analysis of genotype\u2013phenotype correlations.","volume":"61","author":"Kayaalp","year":"1997","journal-title":"Am J Hum Genet"},{"key":"2021121021534309300_B26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1006\/mgme.2000.3038","article-title":"Maternal phenylketonuria: an international study.","volume":"71","author":"Koch","year":"2000","journal-title":"Mol Genet Metab."},{"key":"2021121021534309300_B27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","article-title":"Meta-analysis in clinical research.","volume":"107","author":"L'Abbe KA, Detsky AS, O'Rourke K","year":"1987","journal-title":"Ann Intern Med"},{"key":"2021121021534309300_B28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.genom.1.1.139","article-title":"Genetic screening of newborns.","volume":"1","author":"Levy","year":"2000","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"2021121021534309300_B29","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJM196612152752403","article-title":"Mental retardation in children of phenylketonuric mothers.","volume":"275","author":"Mabry","year":"1966","journal-title":"N Engl J Med"},{"key":"2021121021534309300_B30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF01811706","article-title":"Maternal PKU Collaborative Study: the effect of nutrient intake on pregnancy outcome.","volume":"14","author":"Matalon","year":"1991","journal-title":"J Inherit Metab Dis"},{"key":"2021121021534309300_B31","first-page":"17","article-title":"Maternal PKU: microcephaly at birth and 2 years of age.","volume":"2","author":"Matalon","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"2021121021534309300_B32","first-page":"196","article-title":"Stored Guthrie cards as DNA \u201cbanks.\u201d","volume":"55","author":"McEwen","year":"1994","journal-title":"Am J Hum Genet"},{"key":"2021121021534309300_B33","first-page":"121","article-title":"Congenital heart disease in maternal phenylketonuria: effects of blood phenylalanine and nutrient intake.","volume":"5","author":"Michals-Matalon","year":"1999","journal-title":"MRDD Res Rev"},{"key":"2021121021534309300_B34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1023\/A:1005638627604","article-title":"Brain phenylalanine concentration in the management of adults with phenylketonuria.","volume":"23","author":"Moats","year":"2000","journal-title":"J Inherit Metab Dis"},{"key":"2021121021534309300_B35","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1172\/JCI5017","article-title":"Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria.","volume":"103","author":"Pietz","year":"1999","journal-title":"J Clin Invest"},{"key":"2021121021534309300_B36","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1007\/PL00014246","article-title":"Long-term follow-up of patients with classical phenylketonuria after diet relaxation at 5 years of age.","volume":"155","author":"Rey","year":"1996","journal-title":"Eur J Pediatr"},{"key":"2021121021534309300_B37","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1016\/S0002-8223(97)00406-9","article-title":"Protein intake and plasma phenylalanine concentrations in maternal phenylketonuria.","volume":"97","author":"Rohr","year":"1997","journal-title":"J Am Diet Assoc"},{"key":"2021121021534309300_B38","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1073\/pnas.96.5.2339","article-title":"A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase.","volume":"96","author":"Sarkissian","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021121021534309300_B39","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1007\/PL00014262","article-title":"Intelligence and professional career in young adults treated early for phenylketonuria.","volume":"155","author":"Schmidt","year":"1996","journal-title":"Eur J Pediatr"},{"key":"2021121021534309300_B40","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1172\/JCI3928","article-title":"An ongoing debate over phenylalanine hydroxylase deficiency in phenylketonuria.","volume":"101","author":"Scriver","year":"1998","journal-title":"J Clin Invest"},{"key":"2021121021534309300_B41"},{"key":"2021121021534309300_B42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/adc.66.3.311","article-title":"Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria.","volume":"66","author":"Smith","year":"1991","journal-title":"Arch Dis Child"},{"key":"2021121021534309300_B43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/adc.78.2.116","article-title":"Randomized controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria.","volume":"78","author":"Smith","year":"1998","journal-title":"Arch Dis Child"},{"key":"2021121021534309300_B44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2105\/AJPH.89.5.762","article-title":"The Resource Mothers Program for maternal phenylketonuria.","volume":"89","author":"St James","year":"1999","journal-title":"Am J Public Health"},{"key":"2021121021534309300_B45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1542\/peds.40.1.33","article-title":"Congenital malformations in offspring of phenylketonuric mothers.","volume":"40","author":"Stevenson","year":"1967","journal-title":"Pediatrics"},{"key":"2021121021534309300_B46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0140-6736(90)93401-A","article-title":"Neurological deterioration in young adults with phenylketonuria.","volume":"336","author":"Thompson","year":"1990","journal-title":"Lancet"},{"key":"2021121021534309300_B47","first-page":"388","article-title":"Sequence variation at the phenylalanine hydroxylase gene in the British Isles.","volume":"60","author":"Tyfield","year":"1997","journal-title":"Am J Hum Genet"},{"key":"2021121021534309300_B48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00711827","article-title":"Effect of L-dopa on pattern visual evoked potentials (P-100) and neuropsychological tests in untreated adult patients with phenylketonuria.","volume":"17","author":"Ullrich","year":"1994","journal-title":"J Inherit Metab Dis"},{"key":"2021121021534309300_B49","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2105\/AJPH.85.12.1636","article-title":"Psychosocial factors in maternal phenylketonuria. women's adherence to medical recommendations.","volume":"85","author":"Waisbren","year":"1995","journal-title":"Am J Public Health"},{"key":"2021121021534309300_B50","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jama.283.6.756","article-title":"Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study.","volume":"283","author":"Waisbren","year":"2000","journal-title":"JAMA"},{"key":"2021121021534309300_B51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1005349204797","article-title":"Social factors and the meaning of food in adherence to medical diets: results of a maternal phenylketonuria summer camp.","volume":"20","author":"Waisbren","year":"1997","journal-title":"J Inherit Metab Dis"},{"key":"2021121021534309300_B52","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/BF02073379","article-title":"Biochemical control, genetic analysis and magnetic resonance imaging in patients with phenylketonuria.","volume":"152","author":"Walter","year":"1993","journal-title":"Eur J Pediatr"},{"key":"2021121021534309300_B53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/mgme.2000.2965","article-title":"Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype.","volume":"69","author":"Waters","year":"2000","journal-title":"Molec Genet Metab"},{"key":"2021121021534309300_B54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1005327801588","article-title":"In vivo NMR spectroscopy in patients with phenylketonuria: clinical significance of interindividual differences in brain phenylalanine concentrations.","volume":"21","author":"Weglage","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"2021121021534309300_B55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1005607115309","article-title":"Neurological deterioration in adult phenylketonuria.","volume":"23","author":"Weglage","year":"2000","journal-title":"J Inherit Metab Dis"},{"key":"2021121021534309300_B56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF01953938","article-title":"Deficits in selective and sustained attention processes in early-treated children with phenylketonuria: result of impaired frontal lobe functions?","volume":"155","author":"Weglage","year":"1996","journal-title":"Eur J Pediatr"},{"key":"2021121021534309300_B57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1005328717095","article-title":"Pathogenesis of different clinical outcomes in spite of identical genotypes and comparable blood phenylalanine concentrations in phenylketonurics.","volume":"21","author":"Weglage","year":"1998","journal-title":"J Inherit Metab Dis"},{"key":"2021121021534309300_B58"},{"key":"2021121021534309300_B59","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2307\/1130832","article-title":"Neuropsychology of early-treated phenylketonuria: specific executive function deficits.","volume":"61","author":"Welsh","year":"1990","journal-title":"Child Dev"},{"key":"2021121021534309300_B60","first-page":"155","article-title":"Process of analyses of data: benefits and costs associated with collaborative studies.","volume":"5","author":"Widaman","year":"1999","journal-title":"MRDD Res Rev"},{"key":"2021121021534309300_B61","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.60.6.815","article-title":"Collaborative study of children treated for phenylketonuria: study design.","volume":"60","author":"Williamson","year":"1977","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/4\/972\/895617\/pe1001000972.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/4\/972\/895617\/pe1001000972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:34:54Z","timestamp":1734507294000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/108\/4\/972\/67032\/National-Institutes-of-Health-Consensus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2001,10,1]]},"published-print":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.108.4.972","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10,1]]}}}